Integrated filing Financial
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharma Advanced Research Company Limited (SPARC), the research-focused subsidiary of Sun Pharma, has filed an integrated financial document with the exchanges. This format typically combines the audited/unaudited financial results, notes to accounts, auditor's report, and other disclosures into a single filing — usually submitted alongside quarterly or annual earnings. SPARC is predominantly an R&D-driven entity and has historically reported operating losses as it invests in new drug development pipelines. Specific revenue, PAT, and margin figures from the underlying document are not available from the headline alone and would need to be reviewed in the attached PDF.
For retail investors, integrated filings are routine compliance submissions and rarely trigger an immediate price reaction on their own. The market's response will depend on the actual financial numbers inside — particularly R&D spend, cash burn, licensing income from Sun Pharma, and any updates to the product pipeline. Watch for movement only if the numbers show a meaningful surprise versus expectations.